Chimeric Therapeutics (ASX:CHM) Equity-to-Asset : 0.32 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Chimeric Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was A$5.94 Mil. Chimeric Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was A$18.68 Mil.

The historical rank and industry rank for Chimeric Therapeutics's Equity-to-Asset or its related term are showing as below:

ASX:CHM' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.16 Med: 0.57 Max: 0.74
Current: 0.32

During the past 4 years, the highest Equity to Asset Ratio of Chimeric Therapeutics was 0.74. The lowest was 0.16. And the median was 0.57.

ASX:CHM's Equity-to-Asset is ranked worse than
76.6% of 1487 companies
in the Biotechnology industry
Industry Median: 0.68 vs ASX:CHM: 0.32

Chimeric Therapeutics Equity-to-Asset Historical Data

The historical data trend for Chimeric Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Equity-to-Asset Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Equity-to-Asset

0.69

0.74

0.27

0.16

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Equity-to-Asset	Get a 7-Day Free Trial			0.71	0.27	0.52	0.16	0.32

Competitive Comparison of Chimeric Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Chimeric Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's Equity-to-Asset falls into.

Save Embed

;

Save Embed

;

Chimeric Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Chimeric Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Equity to Asset (A: Jun. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	2.47	/	15.273
	=

Chimeric Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	5.94	/	18.677
	=

Chimeric Therapeutics (ASX:CHM) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Chimeric Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics Headlines

No Headlines